Efficacy of Combining Ultrasound-Guided Needle Release of Transverse Carpal Ligament and Median Nerve Dextrose Water Hydrodissection for Carpal Tunnel Syndrome
Shin Kong Wu Ho-Su Memorial Hospital
102 participants
Jan 1, 2026
INTERVENTIONAL
Conditions
Summary
Carpal tunnel syndrome (CTS) is a common musculoskeletal disorder, which is caused by compression of the median nerve as it travels through the wrist. There are several treatments for CTS, including conservative and surgical options. Though local corticosteroid injection has been considered more effective than physical therapy for treatment of CTS and has significant short-term benefits, long term benefits are not evidenced. Several studies in recent years reported significantly superior longer-term benefit of D5W and PRP compared with corticosteroid injections and other conservative managements. In addition, percutaneous release of the transverse carpal ligament (TCL) was developed to treat CTS in recent years. Because the effectiveness of the recently developed techniques in treating CTS has not been well established, the investigators aim to investigate whether combining US-guided partial release of the transverse carpal ligament with a needle plus D5W hydrodissection is more beneficial for CTS comparing to either treatment alone.
Eligibility
Inclusion Criteria4
- age between 20 to 80 years old
- diagnosed with CTS on the basis of clinical condition and an electrophysiological analysis
- the NRS of pain or paresthesia≧3
- with symptoms lasting for a minimum of 3 months.
Exclusion Criteria5
- history of polyneuropathy, thoracic outlet syndrome, brachial plexopathy, or inflammatory arthropathy
- onset of CTS during pregnancy, hypothyroidism, or systemic infection
- previous corticosteroid injection or wrist surgery for CTS
- hypersensitivity to dextrose injection
- the anatomic structure of the wrist is not suitable for needle release of TCL.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients in the group A will receive 1 session of ultrasound-guided perineural injection with 5ml D5W.
Patients in the group B will receive 1 session of ultrasound-guided partial release of the TCL with a needle plus D5W injection to TCL.
Patients in the group C will receive 1 session of the treatment combining group A and group B. Hydrodissection of the median nerve will be performed before TCL release.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07324005